Certara to be sold, but Arsenal retaining minority ownership stake

Arsenal Capital Partners has announced it is selling its portfolio company, Certara, to EQT VII Fund for $850 million, although, as a part of the deal, it will retain a minority ownership stake.

Certara provides model-informed drug development technology and services, as well as a regulatory science, writing and submission management software and services. It currently serves 1,200 commercial companies, 250 academic institutions and numerous regulatory agencies, across 60 countries.

Headquartered in Princeton, New Jersey with over 500 global employees, including key operations and senior management in Northern Europe, the current management team, led by Dr Edmundo Muniz, PhD, will remain the same.

Stephen McLean, partner at Arsenal and co-head of the healthcare practice, said: “Arsenal’s healthcare team is committed to facilitating systemic improvement in the efficacy and safety of pharmaceutical and biotechnology treatments and cures. We are proud of the significant contribution Certara is making to this critical initiative and the global leadership it has established. We are confident that our new partnership with EQT will enable Certara to further expand its industry leading capabilities.”

“Working with Arsenal has spurred Certara’s growth trajectory, enabling us to refine our strategy, make critical investments and add key capabilities to significantly impact the process of drug development,” added Muniz. “Arsenal is a visionary organization, committed to improving global healthcare and bringing safer medicines to patients. They have been an outstanding partner to Certara. We look forward to the next chapter of Certara’s growth in partnership with EQT and with Arsenal’s continuing support.”